A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer
Acrivon Therapeutics
Summary
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Description
OncoSignature Selected Cohorts (Arms 1 and 2): Participants in Arms 1 \& 2 will be allocated into two arms based on prospectively predicted sensitivity to ACR-368 using the OncoSignature® Companion Diagnostic test, as follows: Arm 1: OncoSignature Positive tumors Arm 2: OncoSignature Negative tumors (completed) OncoSignature Unselected Cohort (Arm 3 \& Arm 4): In Arm 3 and Arm 4, participants will not require a biopsy or OncoSignature result. Participants in Arm 1 and Arm 4 will receive ACR-368 as monotherapy. Participants in Arms 2 and 3 will receive ACR-368 with ULDG sensitization. Par…